Suraksha Diagnostic Limited

Suraksha Diagnostic Limited

CLOSED

IPO Date: 29 Nov - 3 Dec 2024

Listing Date: 6 Dec 2024

Price Range

Rs.420 to Rs.441

Issue Size

846 Cr

Min Investment

14,700

Lot Size

35 Shares

Schedule of Suraksha Diagnostic Limited

Issue open date

29 Nov 2024

Issue close date

3 Dec 2024

UPI mandate deadline

3 Dec 2024 (5 PM)

Allotment finalization

4 Dec 2024

Share credit

5 Dec 2024

Listing date

6 Dec 2024

Mandate end date

17 Dec 2024

Issue size

Funds Raised in the IPOAmount
Overall846 Cr
Fresh Issue0 Cr
Offer for Sale0 Cr

Allotment DetailsNew

Allotment TimelineDetails
Allotment Date4 Dec 2024
Allotment Link{Link}

Grey Market PremiumNew

Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.

DateIpo PriceGMPEstimated Listing Price
6 Dec 202444113454 (2.95%)
5 Dec 202444113454 (2.95%)
4 Dec 202444111452 (2.49%)
3 Dec 20244412443 (0.45%)
2 Dec 20244410441 (0%)
1 Dec 20244410441 (0%)
30 Nov 20244410441 (0%)
29 Nov 20244410441 (0%)
28 Nov 20244410441 (0%)
27 Nov 20244410441 (0%)
26 Nov 20244410441 (0%)

Performance Suraksha Diagnostic Limited

Issue PriceListing GainCurrent Market PriceP/L
Rs.420 to Rs.441 2298 (-4.5%) 279.55-36.61%

About Suraksha Diagnostic Limited

Suraksha Diagnostic Limited, incorporated in 2005, operates as an integrated diagnostic service provider in East India, covering pathology, radiology, and medical consultation. With central reference and satellite labs, along with diagnostic centres, the company provides accessible diagnostic services, accredited by the College of American Pathologists and NABL, across regions including West Bengal, Bihar, Assam, and Meghalaya.

Founded in2005
Managing directorDr. Somnath Chatterjee and Ms. Ritu Mittal
Parent organizationSuraksha Diagnostic Ltd

Financial Overview

Strengths

  • Leading presence in eastern India’s diagnostic market with growth potential in a fragmented industry
  • Provides comprehensive diagnostics including pathology radiology and consultations.
  • Equipped with advanced clinical infrastructure and skilled personnel for reliable services.
  • Recognized brand with a focus on quality supporting individual consumer business.

Risks

  • The company’s business relies heavily on West Bengal and any loss of business in this region may negatively impact overall performance.
  • Keeping up with new tests and technology is essential; falling behind could weaken the company’s competitive edge.
  • The company depends on third-party vendors for testing equipment and supply disruptions could affect operations.
  • Franchisees run many collection centres and failing to meet the required standards could impact quality and reputation.
  • The diagnostics industry is highly competitive which could lead to price cuts that affect profits.
  • The company has significant debt and financial agreements that may reduce flexibility and affect financial health.

Subscription Figures

CategorySubscription (No. of times)
Qualified Institutional Buyers (QIBs)1.74
Non-Institutional Investors (NIIs)1.4
Retail Individual Investors (RIIs)0.94
EmployeeN/A
Total1.27